Research location
Portage
Michigan, United States
Advertisement
Research activity in Portage
Michigan, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Portage
9 linked trials · page 1 of 1A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)NCT01922037 · 2013-06-19 · 1 site observation
COMPLETED
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep ApnoeaNCT01557166 · 2012-06-07 · 1 site observation
COMPLETED
Study of Rivoglitazone in Type 2 Diabetes MellitusNCT00484198 · 2007-04-23 · 1 site observation
COMPLETED
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes MellitusNCT00395512 · 2006-11-01 · 1 site observation
COMPLETED
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy AloneNCT00295633 · 2006-03-01 · 1 site observation
COMPLETED
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)NCT00297115 · 2006-03-01 · 1 site observation
COMPLETED
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderNCT00278941 · 2005-12-01 · 1 site observation
COMPLETED
Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesNCT00106808 · 2005-08-01 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPDNCT00206167 · 2005-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.